The New Jersey Prescription Monitoring Program (NJPMP)  is an important component of the New Jersey Division of Consumer Affairs' initiative to halt the abuse and diversion of prescription drugs.

Established pursuant to N.J.S.A. 45:1-45 et. seq., the NJPMP is a statewide database that collects prescription data on Controlled Dangerous Substances (CDS)  and Human Growth Hormone (HGH)  dispensed in outpatient settings in New Jersey, and by out-of-State pharmacies dispensing into New Jersey.

Pharmacies are required to report information to the NJPMP on a daily basis to the PMP Clearinghouse using the ASAP 4.2 format. Prescriptions must be reported to the database no more than one business day after the date the prescription was dispensed.

Sign Up for E-News

The Division of Consumer Affairs and the NJPMP Administrator keep patient information strictly confidential, in compliance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA)  Privacy and Security Rules.


The website - www.njconsumeraffairs.gog - has a link where reports by health care providers (e.g. physician, pharmacist, etc.) can be sent to the division for suspicious incidents. For example: fraudulent, stolen, or altered prescriptions for a controlled dangerous substance (CDS), a suspicious doctor/pharmacy, an individual obtaining CDS for any purpose other than the treatment of an existing medical condition, such as for purposes of misuse, abuse, or diversion. take any other action the prescriber or pharmacist deems appropriate.


Access to the NJPMP is granted to prescribers, delegates and pharmacists who are licensed by the State of New Jersey and whose licensees are in good standing with their respective licensing boards. Registered prescribers may delegate their authority to access the NJPMP to certain other healthcare  professionals.

Before issuing a prescription, a prescriber or the prescriber's delegate shall access prescription monitoring information for a new or current patient the first time the practitioner prescribes a Schedule II controlled dangerous substance to a patient for acute or chronic pain; and on a quarterly basis (every three months) during the period of time a current patient continues to receive a prescription for a Schedule II controlled dangerous substance for acute or chronic pain.


The New Jersey Division of Consumer Affairs invites all members of the public to help in the fight to halt the abuse and diversion of prescription drugs.

The statistics on prescription drug abuse are staggering.

The 2016 American Society of Addiction Medicine (ASAM)  Facts and Figures notes that "four in five new heroin users started out misusing prescription painkillers."

Every day, 46 Americans die from an overdose caused by prescription painkiller abuse. Overdoses of opioid prescription drugs now kill more people in the U.S. than heroin and cocaine combined.

Consumers can learn the best ways to dispose of unused medications, and to keep medications safe within their homes, at our Project Medicine Drop website.

Individuals seeking additional information about prescription drug abuse – including ways to talk with their family members about the dangers of drug abuse, and information for those struggling with addiction – can find it at our Useful Links page.